The fifth epidermal growth factor-like region of thrombomodulin exerts cytoprotective function and prevents SOS in a murine model

Bone Marrow Transplant. 2017 Jan;52(1):73-79. doi: 10.1038/bmt.2016.195. Epub 2016 Jul 18.

Abstract

The present study found that the fifth epidermal growth factor-like domain of thrombomodulin (TME5) possesses the cytoprotective function in association with an increase in levels of anti-apoptotic myeloid cell leukemia-1 protein in an activated protein C-independent manner in human umbilical vein endothelial cells (HUVECs). Importantly, TME5 counteracted calcineurin inhibitor-induced vascular permeability and successfully prevented monocrotaline-induced sinusoidal obstruction syndrome (SOS) in a murine model. Taken together, TME5 may be useful for preventing or treating lethal complications that develop after hematopoietic stem cell transplantation such as SOS and thrombotic microangiopathy in which endothelial cell damage has a role.

MeSH terms

  • Animals
  • Cytoprotection / drug effects*
  • Epidermal Growth Factor
  • Female
  • Hepatic Veno-Occlusive Disease / chemically induced
  • Hepatic Veno-Occlusive Disease / drug therapy*
  • Hepatic Veno-Occlusive Disease / metabolism
  • Hepatic Veno-Occlusive Disease / pathology
  • Human Umbilical Vein Endothelial Cells / metabolism*
  • Human Umbilical Vein Endothelial Cells / pathology
  • Humans
  • Mice
  • Mice, Inbred ICR
  • Monocrotaline / adverse effects
  • Monocrotaline / pharmacology
  • Protein Domains
  • Thrombomodulin / administration & dosage*
  • Thrombomodulin / chemistry
  • Thrombomodulin / genetics

Substances

  • THBD protein, human
  • THBD protein, mouse
  • Thrombomodulin
  • Epidermal Growth Factor
  • Monocrotaline